UG HEALTHCARE CORPORATIONLTD (SGX:8K7)
UG Healthcare's 1Q22 Update - Production Disruption But Trading Below Book
- UG Healthcare (SGX:8K7)'s 1Q22 PATMI declined 53% y-o-y to S$10.6mil. 1Q22 revenue/PATMI were within expectations at 25%/22% of our FY22e forecasts. Weakness due to declining lower glove prices.
- Factories were shut almost three weeks in July under a government mandated lockdown.
- Industry nitrile glove prices declined significantly q-o-q but latex gloves prices were relatively more stable.
- We are lowering UG Healthcare's FY22e earnings by forecast to S$39mil. We expect 2Q22 results to be stable despite weaker nitrile glove prices. UG Healthcare will benefit from more stable prices of latex gloves that is 50% of revenue. Nitrile glove margins will benefit from declining raw materials due to excess capacity in China. In addition, distribution margins are creeping up as factories aggressive bid for orders.
The Positive
Production is back to norms.
- Following a vaccination rate of the workforce above 80%, UG Healthcare can resume operations back to normal levels. The shutdown in 1Q22 has affected their ability to completely fulfil customer orders given the declining inventory and production uncertainty.
The Negative
Nitrile glove price weakness.
- Industry nitrile glove selling prices continue to decelerate from between US$70 to US$80 (per thousand pieces) in 4Q21 to US$55 to US$60 in 1Q22. We believe prices are now trending around US$35. Latex glove prices are holding up better at around US$33.
Outlook
- Nitrile glove prices are expected to slide further into 2Q22. However, other drivers can keep hold margins relatively stable for UG Healthcare.
- Firstly, latex glove prices are stabilising as competition from China is concentrated in nitrile gloves;
- Secondly, nitrile raw material prices are beginning to decline due to excess capacity built up;
- Thirdly, glove demand is improving due to rising COVID-19 cases and stocking up for the winter season;
- Fourthly, excess production capacity has provided higher bargaining power and margins for distributors. This provides UG Healthcare with an avenue to outsource some of their customer orders to other factories.
Maintain ACCUMULATE with a lower target price of S$0.32, from S$0.63
- We cut FY22e PATMI by 20% to S$39mil. The visibility of glove prices remains an overhang due to the large nitrile capacity coming onstream in China and Malaysia.
- The target price for UG Healthcare is pegged at a 30% discount to the Big 4 Malaysian glove makers. This implies 5x FY22e P/E and a target price of S$0.32, down from S$0.63 previously. Our recommendation for UG Healthcare is maintained at ACCUMULATE. The current UG Healthcare share price is below the book value of S$0.327.
- See
Paul Chew
Phillip Securities Research
|
https://www.stocksbnb.com/
2021-11-18
SGX Stock
Analyst Report
0.32
DOWN
0.630
